Evrys Bio is a privately held biotech company based in Doylestown, Pennsylvania, specializing in the development of next-generation broad-spectrum antiviral therapeutics. Founded in 2012 on groundbreaking discoveries from Princeton University, the company focuses on addressing unique clinical challenges unmet by current antiviral treatments. Evrys Bio leverages its proprietary technology to develop first-in-class antivirals that are safe and effective against drug-resistant viruses. The company has received significant funding, including a $34.3 million award from the Department of Defense, to advance its innovative drug discovery programs.